research use only
Cat.No.S1068
| Related Targets | EGFR VEGFR FGFR PDGFR Src MEK CSF-1R FLT3 HER2 c-Kit |
|---|---|
| Other c-Met Inhibitors | Tepotinib (EMD-1214063) Dihexa SGX-523 PHA-665752 Foretinib (GSK1363089, XL880) SU11274 BMS-777607 JNJ-38877605 Tivantinib PF-04217903 |
|
In vitro |
DMSO
: 9 mg/mL
(19.98 mM)
Water : Insoluble Ethanol : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about PF-02341066 (Crizotinib) solubility in DMSO or water
Read more about PF-02341066 (Crizotinib) working concentrations for cell culture treatment
| Information | PF-02341066 (Crizotinib) is a potent, multi-target ATP-competitive ALK, MET, and ROS1 inhibitor. It blocks ALK/MET/ROS1 and downstream AKT/ERK/STAT3 signaling by binding to the kinase ATP-binding sites, effectively inhibiting tumor cell proliferation, migration, and inducing apoptosis. |
|---|---|
|
Read more about PF-02341066 (Crizotinib) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
Read more about PF-02341066 (Crizotinib) Mechanism of Action Clinical Trials
| Molecular Weight | 450.34 | Formula | C21H22Cl2FN5O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 877399-52-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | PF-02341066 | SMILES | CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N | ||
Read more about storage stability stock solution CAS number SMILES
Read more comparative analysis about PF-02341066 (Crizotinib)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
Could you tell me whether this compound represents the pure R-form, or is it the racemic mixture, so a combination of the S- and the R-form?
Answer:
Our S1068 is the R enantiomer (except batches 05 and 06, which are the racemate), and S7505 is the S enantiomer.